Interactive Brokers Appointed International Broker for Sinopac Securities
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced its appointment as the primary international broker for Sinopac Securities today. Institutional and retail clients of Sinopac can trade US stocks, ETFs, and Fixed Income instruments while also accessing over 90 stock markets worldwide through Interactive Brokers. This initiative between Interactive Brokers LLC and Sinopac strengthens Interactive Brokers’ footprint in the APAC region and adds Taiwan to the over 200 countries and territories worldwide where the company services clients.
“We are pleased to work with Sinopac and bring Interactive Brokers’ global trading capabilities and expertise to Taiwan,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “We recognize the advantage of working with a leading broker with local experience and look forward to serving the needs of this important market and its investors.”
Taiwanese investors will benefit from Interactive Brokers’ powerful trading platforms and advanced technology and tools. Interactive Brokers offers clients the ability to trade fractional shares of eligible US and European stocks as well as ETFs and can accommodate over 100 order types, including algorithmic trading, which is currently unavailable through other brokers in Taiwan. Clients can trade select US ETFs 23½ hours a day, five days a week through Overnight Trading Hours on the IBKR Eos ATS (“IBEOS”). With Overnight Trading Hours, investors across Asia can access US Equity Markets during their trading day and respond to market-moving news at almost any time. The collaboration with Sinopac also enables clients of Interactive Brokers to trade Taiwanese stocks through Sinopac Securities.
Introducing Brokers worldwide use Interactive Brokers’ Prime Broker services to help manage their businesses with efficiency and serve their clients at a lower cost. Through Interactive Brokers, Introducing Brokers can reduce their operational, brokerage, and clearing costs while gaining electronic market access worldwide with the company’s professional, white-branded trading technology. Interactive Brokers’ turnkey solution covers trading, clearing, reporting, and billing and provides the following advantages:
- Support for global regulatory reporting
- Account funding and trading in up to 26 currencies
- Access to stocks, options, futures, currencies, bonds, and funds in over 150 markets from a single unified platform
- No ticket charges, no minimums, and no technology, software, platform, or reporting fees
- Free client relationship management tools
For additional information about Interactive Brokers’ Introducing Broker platform, please visit:
US and Countries Served by IB LLC: https://www.interactivebrokers.com/en/accounts/broker.php
Canada: https://www.interactivebrokers.ca/en/accounts/broker.php
UK: https://www.interactivebrokers.co.uk/en/accounts/broker.php
Western Europe: https://www.interactivebrokers.ie/en/accounts/broker-ie.php
Central Europe: https://www.interactivebrokers.hu/en/accounts/broker-hu.php
Hong Kong: https://www.interactivebrokers.com.hk/en/accounts/broker.php
Singapore: https://www.interactivebrokers.com.sg/en/accounts/broker.php
India: https://www.interactivebrokers.co.in/en/accounts/broker.php
Australia: https://www.interactivebrokers.com.au/en/accounts/broker.php
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 150 markets in numerous countries and currencies from a single unified platform to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. For the fifth consecutive year, Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its March 25, 2022, Best Online Brokers Review.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005686/en/
Contact information
Interactive Brokers Group, Inc
Katherine Ewert, media@ibkr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acuity Knowledge Partners Acquires Ascent18.9.2025 10:30:00 EEST | Press release
Acuity Knowledge Partners (Acuity), a leading global provider of bespoke research, data management, analytics and AI solutions to the financial services sector, has announced that it has exchanged on the acquisition of Ascent. The transaction is expected to close on 30th September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250915732380/en/ L-R: Stewart Smythe, Chief Executive Officer, Ascent; Jon O'Donnell, Chief Operating Officer, Acuity Knowledge Partners, and Robert King, Chief Executive Officer, Acuity Knowledge Partners This strategic move significantly expands Acuity's Data and Technology Services (DTS) division and its offering of technology and AI led services and solutions. Ascent, a leading European provider of AI-powered digital transformation services, supports over 170 clients globally, with 550 data, software, and cloud specialists operating across seven European jurisdictions. “Our acquisition of Asc
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 09:00:00 EEST | Press release
Almirall, S.A. (ALM) a global biopharmaceutical company focused on medical dermatology today announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology 2025 (EADV) in Paris. POSITIVE is the first RWE study in dermatology to use the World Health Organization Well-Being Index (WHO-5) as a primary endpoint. The selection of the abstract as a late breaker at the EADV congress highlights the importance of the findings of the POSITIVE study and its unique approach to evaluating the long-term holistic impact of an advanced treatment in patients with moderate-to-severe psoriasis, a condition that profoundly impairs social, psychological, and physical quality of life, impacting overall well-being1. Two‑Year Real‑World Results from POSITIVE The 24-month, multinational, phase IV observational study enrolled 785 adult patients with moderate-to-severe plaque psoriasis across nine European countries
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 09:00:00 EEST | Press release
Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with confidence. This joint offering provides an end-to-end solution designed to meet evolving regulatory expectations, accelerate adoption
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 08:00:00 EEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 08:00:00 EEST | Press release
Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers. “Ireland is a leading hub for biopharmaceutical manufacturing and innova
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom